{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:56:17Z","timestamp":1792511777475,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lung adenocarcinoma patients are often found to have developed bone metastases at the time of initial diagnosis. With the continuous development of technology, we have successfully entered the era of immunotherapy. This study aimed to determine the efficacy of immunotherapy in lung adenocarcinoma patients with bone metastases (LABM) through a multicenter retrospective analysis and to develop a novel tool to identify the population that could benefit most from immunotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To assess the impact of immunotherapy on LABM in terms of overall survival, we used analytical tools such as Kaplan-Meier analysis, Log-ranch test, and propensity score matching (PSM) method. A predictive model for constructing overall survival was constructed using Cox regression modeling. Based on this, we developed a risk classification system depicting Kaplan-Meier curves for subgroup analysis to determine the optimal beneficiary population for immunotherapy in different risk subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 20073 eligible patients were enrolled in this study, of whom 8010 did not receive immunotherapy, while 12063 patients received immunotherapy. After 1:1 PSM, 15848 patients were successfully coordinated, yielding a balanced cohort. Kaplan-Meier survival curves showed significantly enhanced overall survival (P &amp;lt; 0.001) in patients who received immunotherapy compared to those who did not. The results of Cox regression analyses showed that age, race, sex, primary site, immunotherapy, surgery, chemotherapy, brain metastasis, liver metastasis, lung metastasis, and marital status were independent prognostic factors. The area under the curve for all three cohorts was close to 0.7, indicating that the model was well-discriminating. The calibration curves further proved that the model had a high predictive accuracy. Decision curve analysis demonstrated that the model could achieve a high net clinical benefit. The risk classification system developed based on the model successfully screened the best beneficiary population for immunotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides convincing evidence that immunotherapy provides a significant survival advantage for LABM. Secondly, the clinical tools constructed in this study can help clinicians identify the optimal population to benefit from immunotherapy in LABM, thus enabling precise treatment and avoiding the waste of medical resources and over-treatment of patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1457916","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T08:22:07Z","timestamp":1734078127000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunotherapy for lung adenocarcinoma patients with bone metastases: who really needs it"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhangheng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiling","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21838","article-title":"Global cancer statistics: A healthy population relies on population health","volume":"74","author":"Natia","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21830","article-title":"Cancer statistics, 2024","volume":"74","author":"Rebecca","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Luis","year":"2024","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/S0140-6736(16)32022-0","article-title":"Dynamic contrast-enhanced MRI to predict response to\nvinorelbine-cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and\nbone metastases: a randomised, double-blind, placebo-controlled trial","volume":"388","author":"Rui","year":"2016","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12890-023-02470-z","article-title":"Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study","volume":"23","author":"Ke","year":"2023","journal-title":"BMC Pulm Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12940-024-01094-y","article-title":"Air pollution and survival in patients with Malignant mesothelioma and asbestos-related lung cancer: a follow-up study of 1591 patients in South Korea","volume":"23","author":"Da-An","year":"2024","journal-title":"Environ Health"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062409","article-title":"Nivolumab or atezolizumab in the second-line treatment of advanced non-small cell lung cancer? A prognostic index based on data from daily practice","volume":"12","author":"Magdalena","year":"2023","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5468","article-title":"Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres","volume":"12","author":"Lauren","year":"2022","journal-title":"Cancer Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009039","article-title":"High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)","volume":"12","author":"Myrto","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12943-024-02014-x","article-title":"Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study","volume":"23","author":"Mingchao","year":"2024","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Hossein","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Martin","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Roy","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/17588359241249627","article-title":"Challenges and opportunities in the immunotherapy era: balancing expectations with hope in small-cell lung cancer","volume":"16","author":"Raza","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12885-024-12133-9","article-title":"Reproductive factors and risk of lung cancer among 300,000 Chinese female never-smokers: evidence from the China Kadoorie Biobank study","volume":"24","author":"Marwa","year":"2024","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-079798","article-title":"Adverse independent prognostic effect of initial lung cancer on female patients with second primary breast cancer: a propensity score-matched study based on the SEER database","volume":"14","author":"Dechang","year":"2024","journal-title":"BMJ Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.11.014","article-title":"Associations between sex-specific reproductive factors and risk of new-onset lung cancer among female patients","volume":"166","author":"Yan","year":"2023","journal-title":"Chest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Sabra","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Leena","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"David R","year":"2004","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2011.47","article-title":"Bone marrow and the control of immunity","volume":"9","author":"Ende","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-005-0478-9","article-title":"Surgical treatment of bone metastasis: indications and outcomes","volume":"10","author":"Jun","year":"2005","journal-title":"Int J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.03.013","article-title":"Skeletal metastases in non-small cell lung cancer: a retrospective study","volume":"57","author":"Asuka","year":"2007","journal-title":"Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.11.007","article-title":"The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature","volume":"42","author":"Brindha","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.11.30","article-title":"Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience","volume":"11","author":"Chenxi","year":"2020","journal-title":"J Thorac Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2018.1466895","article-title":"Outcomes of surgery as part of the management of metastatic non-small-cell lung cancer: A surveillance, epidemiology and end results database analysis","volume":"36","author":"Omar","year":"2018","journal-title":"Cancer Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.21037\/atm","article-title":"Surgical resection of primary tumors improved the prognosis of patients with bone metastasis of non-small cell lung cancer: a population-based and propensity score-matched study","volume":"9","author":"Dan","year":"2021","journal-title":"Ann Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01854","article-title":"Electronic patient-reported outcome-based symptom management versus usual care after lung cancer surgery: long-term results of a multicenter, randomized, controlled trial","volume":"42","author":"Wei","year":"2024","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: A randomized clinical trial","volume":"332","author":"Wenfeng","year":"2024","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3600","article-title":"Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study","volume":"30","author":"Rui","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"216569","DOI":"10.1016\/j.canlet.2023.216569","article-title":"Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer","volume":"582","author":"Yufan","year":"2023","journal-title":"Cancer Lett"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v8i15","article-title":"The role of radiation therapy in bone metastases management","volume":"8","author":"Francesca","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1457916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T08:22:10Z","timestamp":1734078130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1457916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2024.1457916"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1457916","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"article-number":"1457916"}}